Oppenheimer resumed coverage on Allogene with a new price target

8/8/24 7:10:59 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Oppenheimer resumed coverage of Allogene with a rating of Outperform and set a new price target of $11.00 from $13.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALLO

Date	Price Target	Rating	Analyst
5/14/2025		Mkt Outperform → Mkt Perform	Citizens JMP
3/14/2025	$5.00	Mkt Perform → Mkt Outperform	Citizens JMP
8/8/2024	$13.00 → $11.00	Outperform	Oppenheimer
5/31/2024	$11.00	Overweight	Piper Sandler
1/5/2024		Mkt Outperform → Mkt Perform	JMP Securities
1/5/2024		Buy → Neutral	Guggenheim
12/8/2023	$7.00	Buy	Citigroup
12/8/2023		Buy	Citigroup